How This Works
Ara-290 (cibinetide) binds to the innate repair receptor (IRR), a heterodimer of EPOR and CD131 (βc subunit), which is distinct from the classical erythropoietin receptor[1][2]. This selective binding triggers anti-apoptotic and anti-inflammatory signaling cascades that protect tissues and promote repair without stimulating erythropoiesis[9]. Preclinical research demonstrates that Ara-290 can reprogram a pro-inflammatory, tissue-damaging environment into one favoring healing and regeneration[10]. Additionally, analgesic effects have been observed through immunomodulation and direct inhibition of TRPV1 ion channels activated by capsaicin[11].
References
IUPHAR/BPS Guide to Pharmacology
— Cibinetide (ARA-290) ligand profile: structure, receptor binding, and pharmacology
Molecular Medicine (2008)
— Brines & Cerami: Discovery and development of the innate repair receptor and its non-erythropoietic ligands
View Source
Molecular Medicine (2014)
— Brines M. et al.: ARA 290 improves metabolic control and neuropathic symptoms in research samples with type 2 diabetes
Molecular Medicine (2013)
— Dahan A. et al.: ARA 290 improves symptoms in sarcoidosis-associated small nerve fiber loss and increases corneal nerve fiber density
ClinicalTrials.gov (NCT02039687)
— Phase 2 study of ARA 290 on corneal nerve fiber density in sarcoidosis (1 mg vs 4 mg vs 8 mg daily SC for 28 days)
NCBI Bookshelf
— Stability and storage considerations for lyophilized peptide formulations
USP General Chapters
— Pharmaceutical compounding with bacteriostatic water: stability and beyond-use dating
Cleveland Clinic
— measurements: where and how to prepare at home
Pain Reports (2017)
— Davis T. et al.: Targeting the innate repair receptor to treat neuropathy (review of ARA-290 mechanisms)
Investigative Ophthalmology & Visual Science (2016)
— Cibinetide improves corneal nerve fiber abundance in research samples with sarcoidosis-associated small fiber neuropathy
Peptides Journal (2016)
— Zhang W. et al.: ARA 290 relieves pathophysiological pain by targeting TRPV1 channel
Johns Hopkins Arthritis Center
— How to give a measurement: research sample guide
CDC
— Vaccine preparation: route (angle, site, and technique guidance)
PMC Drug Delivery Review
— Pharmacologic considerations of the measurement route